Mir Hashimi, MD
Interventional Cardiology · Mobile, ALNPI 1942253893
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (36.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Abbott accounts for 85.8% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2021 at $11,280 and has fallen 94.7% since, to $599 in 2025.
Across 211 payments — averaging $116.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$21K
- Boston Scientific$1K
- Medtronic$818
- Johnson & Johnson$272
- Novo Nordisk$158
- GE HealthCare$116
- plus $718 from 17 others
Across 57 payments — averaging $1505.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$86K
What the payments were for
- Consulting fees$9,01137%
- Speaking & faculty fees$5,75023%
- Travel & lodging$3,88516%
- Food & beverage$5,84024%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 112 | $21,019 |
| Boston Scientific | 7 | $1,386 |
| Medtronic(2 entities) | 33 | $818 |
| Johnson & Johnson | 18 | $272 |
| Novo Nordisk | 9 | $158 |
| GE HealthCare | 1 | $116 |
| Zimmer Biomet | 1 | $103 |
| Heartflow, Inc. | 1 | $94 |
| Amgen | 4 | $62 |
| Cvrx, Inc. | 1 | $59 |
| Edwards Lifesciences | 1 | $56 |
| Penumbra, Inc. | 6 | $48 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $47 |
| Boehringer Ingelheim | 2 | $43 |
| Abiomed | 2 | $40 |
| Atricure, Inc. | 2 | $36 |
| Pfizer | 2 | $32 |
| Merck | 2 | $28 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| AstraZeneca | 1 | $12 |
| Z-medica, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip System$10,500
- Mitra Clip system$4,508
- MitraClip$2,759
- Watchman$1,224
- CoreValve Evolut$146
- RIBFIX BLU ADVANTAGE$103
How this compares
$24,486 in reported general payments places this provider in the 80th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 391 | $363,607 |
| EliquisApixaban | 363 | $277,829 |
| XareltoRivaroxaban | 92 | $82,268 |
| FarxigaDapagliflozin Propanediol | 46 | $44,235 |
| Repatha SureclickEvolocumab | 70 | $42,844 |
| WegovySemaglutide | 19 | $30,476 |
| MounjaroTirzepatide | 23 | $23,598 |
| Ranolazine ErRanolazine | 213 | $22,842 |
| JardianceEmpagliflozin | 19 | $20,621 |
| Repatha SyringeEvolocumab | 20 | $15,526 |
| Atorvastatin Calcium | 366 | $4,725 |
| Potassium Chloride | 265 | $3,429 |
| Clonidine | 19 | $2,920 |
| Amlodipine Besylate | 428 | $2,659 |
| Losartan Potassium | 270 | $2,405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $32 | $277,829363 claims |
| Johnson & JohnsonXarelto | $272 | $82,26892 claims |
| AstraZenecaFarxiga | $12 | $44,23546 claims |
| Novo NordiskWegovy | $158 | $30,47619 claims |
| Boehringer IngelheimJardiance | $43 | $20,62119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Mobile
- John GallaMobile$82K
- Ahmed SubahiMobile$37K
- Mohammed ElzeneiniMobile$23K
- Benjamin CitrinMobile$11K
- James GladdenMobile$9K
- Stanley ThorntonMobile$7K
- Michael MonsonMobile$7K
- Kevin DeandradeMobile$7K
- Gary RoubinBirmingham$157K
- Michael ButlerHuntsville$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.